Lexeo Q4 net loss $25.9M; FDA aligns on LX2006 accelerated path; LX2020 shows protein expression increases

Lexeo Therapeutics, Inc.

Net loss $25.9M ($0.78/sh) for Q4 2024 vs $14.2M; FY net loss $98.3M ($3.09/sh) vs $66.4M.
Cash $128.5M expected to fund operations into 2027.
FDA agrees to use frataxin expression increase from baseline as co-primary endpoint for LX2006 pivotal study.
LX2020 cohort 1: PKP2 protein increased 71% and 115% from baseline; first participant saw 67% PVC reduction.
LX2020 cohort 2 fully enrolled; interim clinical data expected H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.